IMPORTANT Information on Wegovy:

Wegovy®(semaglutide) injection

  • Wegovy®(semaglutide) is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems to help them lose weight and keep the weight off. The subcutaneous injection is generally started at the dose of 0.25 mg weekly and gradually increased every 4 weeks to a maximum of 2.4 mg per week as tolerated under the direction and supervision of healthcare professionals. Wegovy® should be used with a reduced calorie meal plan and increased physical activity.
  • Wegovy® contains semaglutide and should not be used with other semaglutide-containing oral or injectable products or other GLP-1 receptor agonist medicines.
  • Wegovy® should not be used in patients with Medullary thyroid carcinoma (MTC) or family history of MTC, multiple endocrine syndrome type 2 (MEN 2) or hypersensitivity to this class of drugs, It should be avoided or used with caution in patients with history of pancreatitis or at risk for pancreatitis.
  • It should be used with caution or avoided in females of reproductive potential.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy®may affect the way some medicines work and some medicines may affect the way Wegovy®  Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
  • Before using Wegovy tell your healthcare provider if you have any other medical conditions, including pancreatic disorder, diabetes, kidney disease diabetic retinopathy, depression or other mental health issues or planning to become pregnant, are pregnant or plan to become pregnant. Wegovy®may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant, are breastfeeding.

Please check Wegovy.com for further information and to find out if it is covered by your insurance policy


IMPORTANT Information on Saxenda:

Saxenda® (liraglutide) injection

Saxenda® (liraglutide) injection is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or lipid disorders). Saxenda® contains liraglutide and should not be administered together with other liraglutide-containing products or with any other GLP-1 receptor agonist. Please discuss the safety of administering Saxenda with other drugs including weight loss drugs with us. Saxenda is a daily injection that should be administered as you are instructed with gradual increase in the dosage to optimum dose as tolerated.


  • Patients with a personal or family history of MTC or patients with MEN 2 syndrome.
  • Patients with a serious hypersensitivity or allergic reaction to liraglutide.
  • Pregnancy

Drug Interactions

Saxenda® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda.

For more information visit NovoCare.com